false
0000001800
Common Shares, Without Par Value
ABT
0000001800
2026-11-11
2026-11-11
0000001800
us-gaap:CommonStockMember
exch:XCHI
2026-11-11
2026-11-11
0000001800
us-gaap:CommonStockMember
exch:XNYS
2026-11-11
2026-11-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
| Common Shares, Without Par Value |
|
ABT |
|
| Chicago Stock Exchange, Inc. [Member] |
|
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
November 11, 2026
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in charter)
| Illinois |
|
1-2189 |
|
36-0698440 |
| (State or other
Jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
| of
Incorporation) |
|
|
|
Identification No.) |
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(Address of principal executive offices)(Zip
Code)
Registrant’s telephone number, including
area code: (224) 667-6100
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities Registered Pursuant to Section 12(b) of
the Act:
| Title of Each Class |
Trading
Symbol(s) |
Name of Each Exchange
on
Which Registered |
| Common
Shares, Without Par Value |
ABT |
New York Stock Exchange
Chicago Stock Exchange,
Inc. |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
As previously reported, Abbott has Agreements Regarding Change in Control
(“Agreements”) with its named executive officers.
The Agreements provide that if Abbott gives notification of extension
before the Expiration Date (December 31, 2026), the Agreement’s term shall continue through the second anniversary of the Expiration
Date.
On November 11, 2026, Abbott notified the named executive officers,
other than Robert B. Ford, Abbott’s Chairman of the Board and Chief Executive Officer, that the term of the Agreements was extended
through December 31, 2028. Mr. Ford’s Agreement will expire on December 31, 2026.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| |
ABBOTT LABORATORIES |
| |
|
| Date: November 13, 2026 |
By: |
/s/ Philip P. Boudreau |
| |
| Philip P. Boudreau |
| |
| Executive Vice President, Finance and Chief Financial Officer |